findmyKOL

Velimir Luketic, MD

Enriched profile

Professor, Department of Internal Medicine (Hepatology and Nutrition) · VCU Health System

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Richmond, VA · Southeast · United StatesSpecialtyGastroenterologyFocusLiver Disease and Transplantation+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2024–2024NIH funding1992–2010

Velimir Luketic is Professor, Department of Internal Medicine (Hepatology and Nutrition) at VCU Health System. OpenAlex indexes 276 publications with 25,605 citations (h-index 77); ClinicalTrials.gov lists 2 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Gastroenterology profiles in the findmyKOL directory.

Data verified 11 Oct 2026

Overview

Updated 13 Oct 2026

Velimir Luketic, M.D., is Professor, Department of Internal Medicine (Hepatology and Nutrition) at VCU Health System. The public record shows 276 publications with 25,605 citations (h-index 77), centered on Liver Disease and Transplantation, Liver Diseases and Immunity, Liver Disease Diagnosis and Treatment. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 2 companies, 1 NIH-funded awards (1992–2010).

  • Most recent indexed publication: 2026 · The American journal of gastroenterology
  • Top research focus: Liver Disease and Transplantation
  • 2 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 2 companies

Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Viral Hepatitis (B/C)1 trialHepatitis B1 trialHepatitis, Autoimmune1 trial

Research focus

OpenAlex concept fingerprint
Liver Disease and TransplantationLiver Diseases and ImmunityLiver Disease Diagnosis and TreatmentHepatitis C virus researchOrgan Transplantation Techniques and Outcomes

Drugs & molecules

across trials, industry payments and publications
Iqirvogeneric · ElafibranorClinical trials—Industry payments2Publications1

Works with

trial sponsors and companies reporting payments
Biotest Pharmaceuticals CorporationClinical trials1Industry payments—Ipsen Biopharmaceuticals, IncClinical trials—Industry payments1Ipsen Pharma SASClinical trials—Industry payments1Veloxis PharmaceuticalsClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
276publications

Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.

25,605citations

Total citations across indexed works.

77h-index

Hirsch index (OpenAlex). i10-index 164.

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials ↓
2companies · 2024–2024

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 1992–2010

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Oct 2026

Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 13 Oct 2026

2 companies reported payments to CMS in program years 2024–2024. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    93.3%
    Bile Acid72.2%
    Ursodiol100%
    Part D≥31 patients
    Bile acids and derivatives21.1%
    Ocaliva100%
    Part D<11 patients
  • Anti-infectives

    6.7%
    Nucleoside and nucleotide reverse transcriptase inhibitors6.7%
    Vemlidy100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 13 Oct 2026

1 NIH research award on record, funded 1992–2010 per NIH RePORTER. The latest:

Publications

Updated 13 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 13 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Arun Jayant Sanyal169Richard K. Sterling145Mitchell L. Shiffman70Michael A. Fuchs56Melissa J. Contos51Mohammad Shadab Siddiqui44Jasmohan Singh Bajaj44R. Todd Stravitz42Scott C. Matherly41Douglas M. Heuman41R. Todd Stravitz39Robert A. Fisher37James B. Wade33Kris V. Kowdley31Melanie B. White31Leroy R. Thacker29Mitchell L. Shiffman26Marc P. Posner25Richard Todd Stravitz24A. Scott Mills23Gideon Morris Hirschfield20Andrew Fagan17Hannah Lee17J. M. Ham17HoChong Gilles17Sherry L. Boyett16Charlotte M. Hofmann16ADRIAN H. COTTERELL15Daniel G. Maluf15Christopher L. Bowlus15Cynthia Levy15Norah A. Terrault14Carol Sargeant14Edith A. Gavis13Keith D. Lindor13Ariel B. Unser12Anna Suk-Fong Lok12Michael O. Idowu11John Moore Vierling11Chathur Acharya11

Online presence

Updated 13 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • X / Twitter

    x.com/VCU_Liver

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 13 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vcuhealth.org ↗

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.